kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2021-10-3-72-78kpccz-949Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОР. КардиологияREVIEW. CardiologyСовременные проблемы и перспективы развития клеточной терапии на основе мезенхимных клеток сердца в восстановлении сократительной функции миокардаCurrent status, challenges and perspectives of mesenchymal stem cell-based therapy for cardiac regenerationhttps://orcid.org/0000-0002-0182-009XДокшинП. М.DocshinP. M.

Докшин Павел Михайлович - младший научный сотрудник научно-исследовательской лаборатории молекулярной кардиологии и генетики института молекулярной биологии и генетики Национальный МИЦ имени В.А. Алмазова; младший научный сотрудник лаборатории регенеративной биомедицины Институт цитологии РАН.

Ул. Аккуратова, 2, Санкт-Петербург, 197341; Тихорецкий просп., 4, Санкт-Петербург, 194064

Akkuratova St., 2, St. Petersburg, 197341; Tikhoretskiy Ave., 4, St. Petersburg, 19406

pdocshin@icloud.comhttps://orcid.org/0000-0001-7127-7793БейркдарА.BairqdarA.

Бейркдар Ахмад - магистр кафедры эмбриологии биологического факультета.

Университетская наб., 7-9, Санкт-Петербург, 199034

Universitetskaya nab., 7-9, St. Petersburg, 199034

https://orcid.org/0000-0002-0820-2913МалашичеваА. Б.MalashichevaA. B.

Малашичева Анна Борисовна - кандидат биологических наук заведующая лабораторией регенеративной биомедицины Институт цитологии РАН; заведующая научно-исследовательской лаборатории молекулярной кардиологии и генетики института молекулярной биологии и генетики Национальный МИЦ имени В.А. Алмазова; доцент кафедры эмбриологии биологического факультета Санкт-Петербургский ГУ; руководитель лаборатории регенеративной биомедицины Институт цитологии РАН.

Ул. Аккуратова, 2, Санкт-Петербург, 197341; Университетская наб., 7-9, Санкт-Петербург, 199034; Тихорецкий просп., 4, Санкт-Петербург, 194064

Akkuratova St., 2, St. Petersburg, 197341; Universitetskaya nab., 7-9, St. Petersburg, 199034; Tikhoretskiy Ave., 4, St. Petersburg, 194064

Федеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр имени В.А. Алмазова Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение науки Институт цитологии, Российская академия наукРоссияFederal State Budgetary Institution V.A. Almazov National Medical Research Center of the Ministry of Health of the Russian Federation; Federal State Budgetary Institution of Science Institute of Cytology, Russian Academy of SciencesRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный университетРоссияFederal State Budgetary Educational Institution of Higher Education Saint-Petersburg State UniversityRussian FederationФедеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр имени В.А. Алмазова Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный университет; Федеральное государственное бюджетное учреждение науки Институт цитологии, Российская академия наукРоссияFederal State Budgetary Institution V.A. Almazov National Medical Research Center of the Ministry of Health of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education Saint-Petersburg State University; Federal State Budgetary Institution of Science Institute of Cytology, Russian Academy of SciencesRussian Federation2021240920211037278Copyright © Докшин П.М., Бейркдар А., Малашичева А.Б., 20212021Докшин П.М., Бейркдар А., Малашичева А.Б.Docshin P.M., Bairqdar A., Malashicheva A.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/949

Цель. Современные методы лечения сердечной недостаточности лишь купируют симптомы заболевания, но не способствуют полноценному функциональному излечению сердца. Открытие резидентных стволовых клеток сердца дало толчок к развитию клеточной терапии второго поколения, которая быстро перешла от исследований на животных к клиническим испытаниям с тяжелобольными пациентами. Идентифицировано множество популяций клеток в сердце, имеющих свойства стволовых, но обладающих индивидуальными характеристиками, как in vitro, так и in vivo. Результаты клинических исследований продемонстрировали безопасность введения данных клеток, но не доказали значимую эффективность в улучшении сердечной функции, ограничившись незначительными улучшениями систолического давления левого желудочка сердца и уменьшением площади рубца. Тем не менее это показало перспективность данных подходов в лечении сердца и способствовало развитию клеточной терапии уже нового поколения.

Modern methods of treating heart failure are similar to the palliative care, since they mostly relieve the symptoms of the disease. The discovery of resident cardiac stem cells gave impetus to the development of “second generation” cell therapy, which quickly moved from animal research to clinical trials with critically ill patients. Many cardiac side population cells have been identified to have stem cells characteristics and some additional individual characteristics, both in vitro and in vivo. The results of clinical studies demonstrated that the stem cell treatment is safe, however, this type of cell-based therapy did not restore cardiac function. Its effects were limited to mildly improving left ventricular systolic pressure and reducing the scar area. Despite that, the promising nature of these therapeutic approaches for heart diseases have contributed to the development of next-generation cell therapy.

клеточная терапиярегенерация миокардамезенхимные клетки сердцасердечная недостаточностьcell therapymyocardial regenerationcardiac mesenchymal stem cellsheart failureИсследование выполнено при финансовой поддержке гранта РФФИ № 20-015-00574ReferencesWorld Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2021 Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [cited 2021 Jun 11].World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2021 Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [cited 2021 Jun 11].Vagnozzi R.J., Maillet M., Sargent M.A., Khalil H., Johansen A.K.Z., Schwanekamp J.A., York A.J., Huang V, Nahrendorf M., Sadayappan S., Molkentin J.D. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577(7790):405-409. doi: 10.1038/s41586-019-1802-2.Vagnozzi R.J., Maillet M., Sargent M.A., Khalil H., Johansen A.K.Z., Schwanekamp J.A., York A.J., Huang V, Nahrendorf M., Sadayappan S., Molkentin J.D. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577(7790):405-409. doi: 10.1038/s41586-019-1802-2.Shadrin I.Y., Allen B.W., Qian Y, Jackman C.P., Carlson A.L., Juhas M.E., Bursac N.Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat Commun. 2017;8(1):1825.Shadrin I.Y., Allen B.W., Qian Y, Jackman C.P., Carlson A.L., Juhas M.E., Bursac N.Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat Commun. 2017;8(1):1825.Stehlik J., Kobashigawa J., Hunt S.A., Reichenspurner H., Kirklin J.K. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018;137(1):71-87.Stehlik J., Kobashigawa J., Hunt S.A., Reichenspurner H., Kirklin J.K. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018;137(1):71-87.Li L.L., T.-S. Mini Review: Recent Advances in the Cell-Based Therapies for Cardiac Regeneration. Curr Stem Cell Res Ther. 2020;15(8):649-660. doi: 10.2174/1574888X15666200102103755.Li L.L., T.-S. Mini Review: Recent Advances in the Cell-Based Therapies for Cardiac Regeneration. Curr Stem Cell Res Ther. 2020;15(8):649-660. doi: 10.2174/1574888X15666200102103755.Segers V.F.M., Lee R.T. Stem-cell therapy for cardiac disease. Nature. 2008;451(7181):937-42.Segers V.F.M., Lee R.T. Stem-cell therapy for cardiac disease. Nature. 2008;451(7181):937-42.Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701-5. doi: 10.1038/35070587.Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701-5. doi: 10.1038/35070587.van Berlo J.H., Kanisicak O., Maillet M., Vagnozzi R.J., Karch J., Lin S.C., Middleton R.C., Marban E., Molkentin J.D. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature. 2014;509(7500):337-41. doi: 10.1038/nature13309.van Berlo J.H., Kanisicak O., Maillet M., Vagnozzi R.J., Karch J., Lin S.C., Middleton R.C., Marban E., Molkentin J.D. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature. 2014;509(7500):337-41. doi: 10.1038/nature13309.Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., Kasahara H., Rota M., Musso E., Urbanek K., Leri A., Kajstura J., Nadal-Ginard B., Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-76. doi: 10.1016/s0092-8674(03)00687-1.Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., Kasahara H., Rota M., Musso E., Urbanek K., Leri A., Kajstura J., Nadal-Ginard B., Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-76. doi: 10.1016/s0092-8674(03)00687-1.Chong J.J., Yang X., Don C.W., Minami E., Liu Y.W., Weyers J.J., Mahoney WM., Van Biber B., Cook S.M., Palpant N.J., Gantz J.A., Fugate J.A., Muskheli V, Gough G.M., Vogel K.W., Astley C.A., Hotchkiss C.E., Baldessari A., Pabon L., Reinecke H., Gill E.A., Nelson V, Kiem H.P., Laflamme M.A., Murry C.E. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273-7. doi: 10.1038/nature13233.Chong J.J., Yang X., Don C.W., Minami E., Liu Y.W., Weyers J.J., Mahoney WM., Van Biber B., Cook S.M., Palpant N.J., Gantz J.A., Fugate J.A., Muskheli V, Gough G.M., Vogel K.W., Astley C.A., Hotchkiss C.E., Baldessari A., Pabon L., Reinecke H., Gill E.A., Nelson V, Kiem H.P., Laflamme M.A., Murry C.E. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273-7. doi: 10.1038/nature13233.Keith M.C.L, Bolli R. “String Theory” of c-kitpos Cardiac Cells. Circ Res [Internet]. 2015 Mar 27;116(7):1216-30. Available from: https://doi.org/10.n61/CIRCRESAHA.n6.305557. [cited 2021 Jun 11].Keith M.C.L, Bolli R. “String Theory” of c-kitpos Cardiac Cells. Circ Res [Internet]. 2015 Mar 27;116(7):1216-30. Available from: https://doi.org/10.n61/CIRCRESAHA.n6.305557. [cited 2021 Jun 11].Gude N.A., Sussman M.A. Cardiac regenerative therapy: Many paths to repair. Trends Cardiovasc Med. 2020;30(6):338-343. doi: 10.1016/j.tcm.2019.08.009Gude N.A., Sussman M.A. Cardiac regenerative therapy: Many paths to repair. Trends Cardiovasc Med. 2020;30(6):338-343. doi: 10.1016/j.tcm.2019.08.009Santini M.P., Forte E., Harvey R.P, Kovacic J.C. Developmental origin and lineage plasticity of endogenous cardiac stem cells. Development. 2016;143(8):1242-58. doi: 10.1242/dev.111591.Santini M.P., Forte E., Harvey R.P, Kovacic J.C. Developmental origin and lineage plasticity of endogenous cardiac stem cells. Development. 2016;143(8):1242-58. doi: 10.1242/dev.111591.Li M., Naqvi N., Yahiro E., Liu K., Powell PC., Bradley W.E., Martin D.I., Graham R.M., Dell'Italia L.J., Husain A. c-kit is required for cardiomyocyte terminal differentiation. Circ Res. 2008;102(6):677-85. doi: 10.1161/CIRCRESAHA.107.161737.Li M., Naqvi N., Yahiro E., Liu K., Powell PC., Bradley W.E., Martin D.I., Graham R.M., Dell'Italia L.J., Husain A. c-kit is required for cardiomyocyte terminal differentiation. Circ Res. 2008;102(6):677-85. doi: 10.1161/CIRCRESAHA.107.161737.Barry R Davis. Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF). A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF. 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02501811. [cited 2021 Jun 11].Barry R Davis. Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF). A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF. 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02501811. [cited 2021 Jun 11].Chong J.J., Chandrakanthan V, Xaymardan M., Asli N. S., Li J., Ahmed I., Heffernan C., Menon M.K., Scarlett C.J., Rashidianfar A., Biben C., Zoellner H., Colvin E.K., Pimanda J.E., Biankin A.V, Zhou B., Pu W.T., Prall O.W, Harvey R.P. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell. 2011;9(6):527-40. doi: 10.1016/j.stem.2011.10.002.Chong J.J., Chandrakanthan V, Xaymardan M., Asli N. S., Li J., Ahmed I., Heffernan C., Menon M.K., Scarlett C.J., Rashidianfar A., Biben C., Zoellner H., Colvin E.K., Pimanda J.E., Biankin A.V, Zhou B., Pu W.T., Prall O.W, Harvey R.P. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell. 2011;9(6):527-40. doi: 10.1016/j.stem.2011.10.002.Soriano P The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development. 1997;124(14):2691-700.Soriano P The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development. 1997;124(14):2691-700.Ball S.G., Worthington J.J., Canfield A.E., Merry C.L.R., Kielty C.M. Mesenchymal stromal cells: Inhibiting PDGF receptors or depleting fibronectin induces mesodermal progenitors with endothelial potential. Stem Cells. 2014;32(3):694-705.Ball S.G., Worthington J.J., Canfield A.E., Merry C.L.R., Kielty C.M. Mesenchymal stromal cells: Inhibiting PDGF receptors or depleting fibronectin induces mesodermal progenitors with endothelial potential. Stem Cells. 2014;32(3):694-705.Noseda M., Harada M., McSweeney S., Leja T., Belian E., Stuckey D.J., et al. PDGFRa demarcates the cardiogenic clonogenic Sca1+ stem/progenitor cell in adult murine myocardium. Nat Commun. 2015; 6: 6930. doi:10.1038/ncomms7930Noseda M., Harada M., McSweeney S., Leja T., Belian E., Stuckey D.J., et al. PDGFRa demarcates the cardiogenic clonogenic Sca1+ stem/progenitor cell in adult murine myocardium. Nat Commun. 2015; 6: 6930. doi:10.1038/ncomms7930Cai C.L., Liang X., Shi Y, Chu P.H., Pfaff S.L., Chen J., Evans S. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell. 2003;5(6):877-89. doi: 10.1016/ s1534-5807(03)00363-0.Cai C.L., Liang X., Shi Y, Chu P.H., Pfaff S.L., Chen J., Evans S. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell. 2003;5(6):877-89. doi: 10.1016/ s1534-5807(03)00363-0.Laugwitz KL, Moretti A, Caron L, Nakano A, Chien KR. Islet1 cardiovascular progenitors: A single source for heart lineages? Development. 2008; 135: 193-205. doi:10.1242/dev.001883Laugwitz KL, Moretti A, Caron L, Nakano A, Chien KR. Islet1 cardiovascular progenitors: A single source for heart lineages? Development. 2008; 135: 193-205. doi:10.1242/dev.001883Laugwitz K.L., Moretti A., Lam J., Gruber P., Chen Y., Woodard S., Lin L.Z., Cai C.L., Lu M.M., Reth M., Platoshyn O. , Yuan J.X., Evans S., Chien K.R. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433(7026):647-53. doi: 10.1038/nature03215.Laugwitz K.L., Moretti A., Lam J., Gruber P., Chen Y., Woodard S., Lin L.Z., Cai C.L., Lu M.M., Reth M., Platoshyn O. , Yuan J.X., Evans S., Chien K.R. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433(7026):647-53. doi: 10.1038/nature03215.Menasche P., Vanneaux V., Hagege A., Bel A., Cholley B., Parouchev A., et al. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2018 Jan;71(4):429-38. doi: 10.1016/j.jacc.2017.11.047.Menasche P., Vanneaux V., Hagege A., Bel A., Cholley B., Parouchev A., et al. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2018 Jan;71(4):429-38. doi: 10.1016/j.jacc.2017.11.047.Smith R.R., Barile L., Cho H.C., Leppo M.K., Hare J.M., Messina E., et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115(7):896-908.Smith R.R., Barile L., Cho H.C., Leppo M.K., Hare J.M., Messina E., et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115(7):896-908.Oh H., Bradfute S.B., Gallardo T.D., Nakamura T., Gaussin V., Mishina Y., Pocius J., Michael L.H., Behringer R.R., Garry D.J., Entman M.L., Schneider M.D. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313-8. doi: 10.1073/pnas.2132126100.Oh H., Bradfute S.B., Gallardo T.D., Nakamura T., Gaussin V., Mishina Y., Pocius J., Michael L.H., Behringer R.R., Garry D.J., Entman M.L., Schneider M.D. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313-8. doi: 10.1073/pnas.2132126100.Li T.S., Cheng K., Lee S.T., Matsushita S., Davis D., Malliaras K., Zhang Y., Matsushita N., Smith R.R., Marban E. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells. 2010;28(11):2088-98. doi: 10.1002/stem.532.Li T.S., Cheng K., Lee S.T., Matsushita S., Davis D., Malliaras K., Zhang Y., Matsushita N., Smith R.R., Marban E. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells. 2010;28(11):2088-98. doi: 10.1002/stem.532.Ye J., Boyle A.J., Shih H., Sievers R.E., Wang Z.E., Gormley M., Yeghiazarians Y CD45-positive cells are not an essential component in cardiosphere formation. Cell Tissue Res. 2013;351(1):201-5. doi: 10.1007/s00441-012-1511-8.Ye J., Boyle A.J., Shih H., Sievers R.E., Wang Z.E., Gormley M., Yeghiazarians Y CD45-positive cells are not an essential component in cardiosphere formation. Cell Tissue Res. 2013;351(1):201-5. doi: 10.1007/s00441-012-1511-8.Malliaras K., Makkar R.R., Smith R.R., Cheng K., Wu E., Bonow R.O., Marban L., Mendizabal A., Cingolani E., Johnston P.V., Gerstenblith G., Schuleri K.H., Lardo A.C., Marban E. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110-22. doi: 10.1016/j.jacc.2013.08.7Malliaras K., Makkar R.R., Smith R.R., Cheng K., Wu E., Bonow R.O., Marban L., Mendizabal A., Cingolani E., Johnston P.V., Gerstenblith G., Schuleri K.H., Lardo A.C., Marban E. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110-22. doi: 10.1016/j.jacc.2013.08.7Makkar R.R., Smith R.R., Cheng K., Malliaras K., Thomson L.E., Berman D., Czer L.S., Marban L., Mendizabal A., Johnston PV, Russell S.D., Schuleri K.H., Lardo A.C., Gerstenblith G., Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904. doi: 10.1016/S0140-6736(12)60195-0.Makkar R.R., Smith R.R., Cheng K., Malliaras K., Thomson L.E., Berman D., Czer L.S., Marban L., Mendizabal A., Johnston PV, Russell S.D., Schuleri K.H., Lardo A.C., Gerstenblith G., Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904. doi: 10.1016/S0140-6736(12)60195-0.Makkar R.R., Kereiakes D.J., Aguirre F., Kowalchuk G., Chakravarty T., Malliaras K., Francis G.S., Povsic T.J., Schatz R., Traverse J.H., Pogoda J.M., Smith R.R., Marban L., Ascheim D.D., Ostovaneh M.R., Lima J.A.C., DeMaria A., Marban E., Henry T.D. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2020;41(36):3451-3458. doi: 10.1093/eurheartj/ehaa541.Makkar R.R., Kereiakes D.J., Aguirre F., Kowalchuk G., Chakravarty T., Malliaras K., Francis G.S., Povsic T.J., Schatz R., Traverse J.H., Pogoda J.M., Smith R.R., Marban L., Ascheim D.D., Ostovaneh M.R., Lima J.A.C., DeMaria A., Marban E., Henry T.D. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2020;41(36):3451-3458. doi: 10.1093/eurheartj/ehaa541.Balbi C., Vassalli G. Exosomes: Beyond stem cells for cardiac protection and repair. Stem Cells. 2020;38(11):1387-1399. doi: 10.1002/stem.3261Balbi C., Vassalli G. Exosomes: Beyond stem cells for cardiac protection and repair. Stem Cells. 2020;38(11):1387-1399. doi: 10.1002/stem.3261Liu C., Han D., Liang P, Li Y., Cao F. The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease. Front Cell Dev Biol. 2021; 9: 636136. . doi: 10.3389/fcell.2021.636136Liu C., Han D., Liang P, Li Y., Cao F. The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease. Front Cell Dev Biol. 2021; 9: 636136. . doi: 10.3389/fcell.2021.636136Rheault-Henry M, White I, Grover D, Atoui R. Stem cell therapy for heart failure: Medical breakthrough, or dead end? World J Stem Cells. 2021; 13(4): 236-259. doi: 10.4252/wjsc.v13.i4.236Rheault-Henry M, White I, Grover D, Atoui R. Stem cell therapy for heart failure: Medical breakthrough, or dead end? World J Stem Cells. 2021; 13(4): 236-259. doi: 10.4252/wjsc.v13.i4.236Vagnozzi R.J., Maillet M., Sargent M.A., Khalil H., Johansen A.K.Z., Schwanekamp J.A., York A.J., Huang V., Nahrendorf M., Sadayappan S., Molkentin J.D. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577(7790):405-409. doi: 10.1038/s41586-019-1802-2Vagnozzi R.J., Maillet M., Sargent M.A., Khalil H., Johansen A.K.Z., Schwanekamp J.A., York A.J., Huang V., Nahrendorf M., Sadayappan S., Molkentin J.D. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577(7790):405-409. doi: 10.1038/s41586-019-1802-2

The authors declare that there are no conflicts of interest present.